NCT02506556 - Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 7, 2015

Primary Completion Date

October 26, 2021

Study Completion Date

October 26, 2021

Conditions

Metastatic Breast Cancer

Interventions

DRUG

BYl719

"Treatment: BYL719 350mg orally daily Treatment will be given daily until progression, undue adverse events or withdrawal of consent.~Dose reductions (two levels) are allowed. Each cycle is 28 days"

Trial Locations (1)

3002

Peter MacCallum Cancer Centre, East Melbourne